All In Biotech

Drug Trial Radar · NCT07499544

A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)

A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Apr 22, 2026

Primary completion

Sep 12, 2028

Study completion Jan 29, 2030

Sponsor

Lead sponsor
Huahui HealthIndustry
Sponsor type
Industry
First posted
Mar 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.

Conditions

  • Chronic Hepatitis D Infection

Interventions

  • Libevitug 20 mg/kgDrug

    Route of administration: intravenous infusion

  • Libevitug 10 mg/kgDrug

    Route of administration: intravenous infusion

  • Delayed treatment with libevitugOther

    Route of administration: intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with HDV RNA below LLOQ with TND or a decrease of ≥ 2 log10 from baseline, and ALT normalization at Week 48 of the treatment periodTime frame: Week 48

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Site 201

    Garden Grove, California · Recruiting

  • Site 101

    Changchun, Jilin, China · Recruiting

  • Site 104

    Kashgar, Xinjiang Uygur Autonomous Region, China · Recruiting

  • Site 103

    Ürümqi, Xinjiang Uygur Autonomous Region, China · Recruiting

  • Site 303

    Rawalpindi, Punjab Province, Pakistan · Recruiting

  • Site 301

    Karachi, Sindh, Pakistan · Recruiting

  • Site 302

    Karachi, Sindh, Pakistan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.